Ayati Devices, a Bengaluru-based medical technology and device manufacturing company developing precision diagnostic solutions for diabetic foot complications and peripheral vascular disease, has raisedINR 15 Crore in a Pre-Series Afunding round led byInflexor Ventures. This marks the company's first institutional investment and will accelerate the commercialisation of its next-generation diagnostic technologies, expand its domestic and international presence, strengthen manufacturing capabilities, and deepen investments in research, regulatory approvals, artificial intelligence, and global talent.Ayati Devices has been incubated at IITB-SINE as part of the institute’s translational research program. India's medical devices sector is accelerating on innovation and government incentives, even as diabetes becomes one of the world's biggest health challenges. Over 90 million Indians live with diabetes. Many lose foot sensation silently until complications strike, and over 50,000 lower-limb amputations occur in India each year, most preventable through timely diagnosis. Founded by Nishant Kathpal, Ayati Devices builds clinically accurate, portable, and affordable diagnostic technologies that bring preventive care beyond tertiary hospitals into primary care centres and diabetes clinics. Ayati's portfolio covers the full diabetic foot diagnostic pathway. Vibrasense delivers clinician-independent neuropathy screening in under five minutes; Vibrasense+T adds large- and small-fibre nerve assessment. Vasosense detects Peripheral Artery Disease in two minutes without a specialist, while Angiocam turns real-time tissue perfusion imaging, once prohibitively expensive, into an accessible, portable tool. Completing the suite, the PODIA Trolley offers a pay-per-test screening station with zero upfront capital investment. Ayati's technologies already hold regulatory clearances across major global markets, including CDSCO (India), the U.S. FDA, CE Mark (Europe), and approvals in Sri Lanka, Malaysia, and the UAE. The company has deployed over 10,000 devices across 30+ countries, backed by a growing international distributor network and clinical deployments at leading institutions such as Medicover Hospital and Aster Hospital. .. The addressable market spans $15 billion globally and $1.4 billion in India alone, across diabetic neuropathy, peripheral vascular disease, and tissue perfusion imaging. Ayati's technology also extends into plastic surgery, wound care, burn management, cardiovascular diagnostics, and reconstructive medicine, widening its long-term potential. The capital will fund Angiocam's commercialisation, expand go-to-market operations at home and abroad, strengthen manufacturing and supply chain capacity, accelerate R&D in AI-enabled diagnostics, secure further regulatory approvals, grow the IP portfolio, and build out engineering, clinical, regulatory, and global business development teams. Looking ahead, Ayati will deepen its presence across Europe,
